Viracta Therapeutics, Inc. Overview
Pro stress-test →Viracta Therapeutics is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers. Its lead product candidate is Nana-val, an all-oral combination therapy of nanatinostat and valganciclovir. The company targets unmet needs in EBV-associated malignancies with an innovative viral gene activation approach.
Strategic Profile
Pro stress-test →The company contributes to a growing body of research aimed at tackling malignancies that are difficult to treat with conventional therapies. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for relapsed/refractory EBV+ lymphoma, and a Phase 1b/2 trial for EBV+ recurrent or metastatic nasopharyngeal carcinoma.
Competitive Landscape
Pro stress-test →Viracta competes in the niche viral oncology space, with indirect competition from broader EBV+ cancer programs at larger pharma and biotech companies. Direct competitors are limited due to the specialized focus on viral gene activation. The company's all-oral combination approach differentiates it from traditional chemotherapy and checkpoint inhibitors used in lymphoma and head/neck cancers.
Industry Context
Viracta Therapeutics, Inc. operates in Viral oncology therapeutics.
Key facts
Founded: N/A · Headquarters: Cardiff, US · Employees: N/A · Revenue: $0 · Market cap: $0.39M